ReviewBiotechnology journal2026
Synthetic Biology of Sclareol: From the Plant Biosynthetic Pathway to Engineered Microbial and Photosynthetic Chassis.
Review in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sclareol is a highly valued bicyclic diterpene widely used as a precursor for the fragrance ambroxide and has also attracted interest as a bioactive natural product. Traditional production relies heavily on plant extraction, primarily from Salvia sclarea, an approach constrained by environmental variability, long cultivation cycles, and costly downstream purification. To overcome these supply bottlenecks, synthetic biology-enabled biomanufacturing has emerged as a sustainable and scalable alternative. Recent advances in synthetic biology and metabolic engineering have enabled the elucidation and reconstruction of the sclareol biosynthetic pathway in heterologous hosts. This review summarizes current knowledge of sclareol biosynthesis, highlights representative engineering strategies for its production in microbial cell factories, while briefly introducing emerging photosynthetic and plant-based platforms as complementary green production systems. Finally, we outline the current challenges and future perspectives for the industrial biomanufacturing of sclareol and other high-value terpenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.